Michael Makris/LinkedIn
Apr 3, 2026, 15:51
Michael Makris: Approved but Unavailable Hemophilia B Gene Therapy Remains Out of Reach
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”If you are hoping to have gene therapy for hemophilia B you will have to wait, as currently there is no product available for use outside China.
Hemgenix is the only FDA/EMA approved gene therapy that is commercially available, but the company making it has announced that they do not have any product due to a manufacturing issue. They stress that this is not a safety issue.
The Chinese product is only approved for use in China, and it is at least theoretically possible to travel to have the infusion in Shanghai.”
Other posts featuring Michael Makris on Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants